Formoterol/glycopyrrolate

Drug Profile

Formoterol/glycopyrrolate

Alternative Names: BEVESPI AEROSPHERE; GFF MDI; Glycopyrrolate/formoterol; PT-003; PT001/PT005; PT003-GFF; PT005/PT001

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 10 Jul 2017 Launched for Chronic obstructive pulmonary disease in USA (Inhalation) before July 2017 (AstraZeneca pipeline, July 2017)
  • 10 Jul 2017 AstraZeneca announces intention to submit MAA in the European Union for Chronic obstructive pulmonary disease in H1-2017 (AstraZeneca pipeline, July 2017)
  • 10 Jul 2017 AstraZeneca announces intention to submit regulatory filings for Chronic obstructive pulmonary disease in Japan and China in 2018 (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top